Replies to post #2898 on Galectin Therapeutics Inc. (GALT)

[biotech2010]

It's NVS and CNAT, not TBRA. TBRA was acquired by Allergan. CNAT has positive efficacy on a Phase 2 trial and received $50M from NVS plus the highly likely potential of up to $1B plus royalties from them as well and their market cap is $140M-if GALT is worth more than the current market cap then CNAT should be $25-$30, not $5

You are parsing my comment, I said they need a postive CX trial result to have any kind of valuation, those of you who think the minimal results for skin and cancer will have any affect on the valuation are living in a dream world.